Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability

SM Evans, FR Funderburk and RR Griffiths

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Zolpidem, which is currently marketed in Europe as a hypnotic, is a short-duration imidazopyridine whose actions are mediated at the gamma- aminobutyric acid benzodiazepine receptor complex. However, zolpidem produces a variety of biochemical differences from classic benzodiazepine agonists including showing selectivity for the central BZ1 (omega 1) receptor subtype as well as showing a different pattern of distribution of binding sites. This study compared zolpidem to the benzodiazepine hypnotic triazolam in 15 healthy male volunteers with histories of sedative drug abuse. Placebo, zolpidem (15, 30 and 45 mg) and triazolam (0.25, 0.5 and 0.75 mg) were administered p.o. in a mixed sequence in a double-blind, cross-over design. The onset time with zolpidem was faster than with triazolam, with peak effects of both drugs occurring at 1 to 2 hr after administration. Both zolpidem and triazolam produced dose-related decrements in performance on various performance tasks including circular lights, reaction time, balance, number recall and the digit symbol substitution test. Both drugs also produced similar dose-related changes on various observer ratings including overall strength of drug effect. Triazolam, but not zolpidem, increased subject- and observer-rated sleepiness and produced greater impairment on a picture memory task. Zolpidem, but not triazolam, produced increases in subject ratings of various somatic symptoms (e.g., dizzy, anxious and queasy) and there were 9 days on which subjects vomited after zolpidem, but none after triazolam. Although the highest dose of both drugs was identified by subjects as being active, the highest dose of triazolam was identified as being barbiturate, benzodiazepine or alcohol, almost twice as often as the highest dose of zolpidem. Overall, this study shows that although zolpidem produces many effects in common with triazolam, it also has a unique profile of effects distinguishable from classic benzodiazepine agonists. The mechanism(s) underlying these differences is unclear, but may be related to the atypical biochemical profile of zolpidem.

Volume 255, Issue 3, pp. 1246-1255, 12/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. P. Carter, R. R. Griffiths, P. E. Suess, J. H. Casada, C. L. Wallace, and J. D. Roache Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 749 - 759. [Abstract] [Full Text] [PDF]

				M. W. Johnson, P. E. Suess, and R. R. Griffiths Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry, October 1, 2006; 63(10): 1149 - 1157. [Abstract] [Full Text] [PDF]

				D. J. Nutt NICE: The National Institute of Clinical Excellence - or Eccentricity? Reflections on the Z-drugs as hypnotics J Psychopharmacol, March 1, 2005; 19(2): 125 - 127. [PDF]

				L. R Rappa, M. Larose-Pierre, D. R Payne, N. E Eraikhuemen, D. M Lanes, and M. L Kearson Detoxification from High-Dose Zolpidem Using Diazepam Ann. Pharmacother., April 1, 2004; 38(4): 590 - 594. [Abstract] [Full Text] [PDF]

				I. A. Liappas, P. N. Malitas, N. P. Dimopoulos, O. E. Gitsa, A. I. Liappas, Ch. K. Nikolaou, and G. N. Christodoulou Zolpidem dependence case series: possible neurobiological mechanisms and clinical management J Psychopharmacol, January 1, 2003; 17(1): 131 - 135. [Abstract] [PDF]

				C. A. Simpson and C. R. Rush Acute performance-impairing and subject-rated effects of triazolam and temazepam, alone and in combination with ethanol, in humans J Psychopharmacol, January 1, 2002; 16(1): 23 - 34. [Abstract] [PDF]

				M. D. Higbee, C. M. Plaza, and J. Dunkelbarger-Reed Understanding and Managing Sleep Difficulties in the Elderly Journal of Pharmacy Practice, August 1, 2000; 13(4): 316 - 326. [Abstract] [PDF]

				J. Auta, A. Guidotti, and E. Costa Imidazenil prevention of alprazolam-induced acquisition deficit in patas monkeys is devoid of tolerance PNAS, February 29, 2000; 97(5): 2314 - 2319. [Abstract] [Full Text] [PDF]

				J. K. Rowlett, R. D. Spealman, and S. Lelas Discriminative Stimulus Effects of Zolpidem in Squirrel Monkeys: Comparison with Conventional Benzodiazepines and Sedative-Hypnotics J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1233 - 1241. [Abstract] [Full Text]

				P. Mikolajczak, I. Okulicz-Kozaryn, K. Szczawinska, E. Kaminska, and K. Kus ZOLPIDEM INVOLVEMENT ON MEMORY AND HYPNOTIC EFFECT OF ETHANOL IN CHRONICALLY ETHANOL-TREATED RATS Alcohol Alcohol., July 1, 1999; 34(4): 511 - 519. [Abstract] [Full Text] [PDF]

				M. E. Dieperink and L. Drogemuller Zolpidem for Insomnia Related to PTSD Psychiatr Serv, March 1, 1999; 50(3): 421 - 421. [Full Text] [PDF]

				M. Z. Mintzer and R. R. Griffiths Selective effects of zolpidem on human memory functions J Psychopharmacol, January 1, 1999; 13(1): 18 - 31. [Abstract] [PDF]

				G. Darcourt, D. Pringuey, D. Salliere, and J. Lavoisy The safety and tolerability of zolpidem -- an update J Psychopharmacol, January 1, 1999; 13(1): 81 - 93. [Abstract] [PDF]

				E. M. Weerts, N. A. Ator, D. M. Grech, and R. R. Griffiths Zolpidem Physical Dependence Assessed Across Increasing Doses Under a Once-Daily Dosing Regimen in Baboons J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 41 - 53. [Abstract] [Full Text]

				A. Ravishankar and T. Carnwath Zolpidem tolerance and dependence --two case reports J Psychopharmacol, January 1, 1998; 12(1): 103 - 104. [Abstract] [PDF]

				C. R. Rush, S. Madakasira, N. H. Goldman, W. L. Woolverton, and J. K. Rowlett Discriminative Stimulus Effects of Zolpidem in Pentobarbital-Trained Subjects: II. Comparison with Triazolam and Caffeine in Humans J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 174 - 188. [Abstract] [Full Text]

				{blacktriangledown}Zolpidem - a hypnotic with a difference ? DTB, May 1, 1995; 33(5): 37 - 39. [Abstract] [Full Text] [PDF]

				C. A. Gericke and A. C. Ludolph Chronic Abuse of Zolpidem JAMA, December 14, 1994; 272(22): 1721 - 1722. [Abstract] [PDF]